Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AD-209 in Essential Hypertension
NCT06348576Phase 3Recruiting
- Sponsor
- Addpharma, Inc.
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, amlodipine, chlorthalidone in essential hypertension, sponsored by Addpharma, Inc.. Started May 2024; status: recruiting.
02
Drugs
telmisartanamlodipinechlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06348576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348576.